In today’s fast-paced world, maintaining optimal health is paramount, especially for men who may face unique health ...

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...

Benign Prostatic Hyperplasia (BPH), a non-cancerous enlargement of the prostate gland, is a common condition that affects nearly 50 per cent of men over the age of 60. The condition often comes ...

The TrueScreen commercialisation project is dedicated to developing a non-invasive, urine-based diagnostic solution for urological cancers, especially prostate cancer ... and patient-friendly ...

The size of a man’s prostate varies from person to person. Size is just one of the many factors we consider when determining whether a man needs treatment for BPH. Our doctors use a variety of tools ...

AstraZeneca had a disappointing trial readout with its AKT inhibitor Truqap in breast cancer in June, so unsurprisingly it is trumpeting a first-in-class win for the drug in prostate cancer.

"While there have been certain mischaracterizations regarding the updated guidelines leading to confusion, extensive published evidence shows that Prolaris is a clinically recognized and effective ...